These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4127674)

  • 1. Letter: Plasma biochemistry in haemodialysed patients.
    Bishop MC
    Lancet; 1973 Dec; 2(7841):1328-9. PubMed ID: 4127674
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-protein-bound hydroxyproline in plasma in renal bone disease.
    Bishop MC; Smith R
    Clin Chim Acta; 1971 Jul; 33(2):403-8. PubMed ID: 5119316
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum hydroxyproline and renal osteodystrophy in patients maintained on haemodialysis.
    Goulding A; McChesney R; Irvine RO; Dixon SR
    N Z Med J; 1974 Dec; 80(530):540-4. PubMed ID: 4615274
    [No Abstract]   [Full Text] [Related]  

  • 4. [Bone metabolism disorders. Pathogenesis and diagnosis].
    Fischer JA
    Z Orthop Ihre Grenzgeb; 1972 Jun; 110(3):280-92. PubMed ID: 4263211
    [No Abstract]   [Full Text] [Related]  

  • 5. [Uremic osteodystrophy. Critical evaluation of the radiologic and humoral indices of bone resorption].
    Galmozzi C; Casati S; Rivolta E; De Vecchi A; Imbasciati E; Cecchettin M; Brancaccio D; Ponticelli C
    Minerva Nefrol; 1979; 26(3):405-8. PubMed ID: 262283
    [No Abstract]   [Full Text] [Related]  

  • 6. The hydroxyproline content of plasma of patients with impaired renal function.
    Hart W; Duursma SA; Visser WJ; Njio LK
    Clin Nephrol; 1975; 4(3):104-8. PubMed ID: 1183097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma calcium and magnesium fractions in chronic-renal-failure patients on maintenance haemodialysis.
    Varghese Z; Moorhead JF; Wills MR
    Lancet; 1973 Nov; 302(7836):985-8. PubMed ID: 4127276
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma hydroxyproline in renal osteodystrophy.
    Varghese Z; Moorhead JF; Tatler GL; Baillod RA; Wills MR
    Proc Eur Dial Transplant Assoc; 1973; 10(0):187-96. PubMed ID: 4802560
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma hydroxyproline fractions in patients with dialysis osteodystrophy.
    Varghese Z; Moorhead JF; Wills MR
    Clin Chim Acta; 1981 Feb; 110(1):105-11. PubMed ID: 7214708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients.
    Couttenye MM; D'Haese PC; Van Hoof VO; Lemoniatou E; Goodman W; Verpooten GA; De Broe ME
    Nephrol Dial Transplant; 1996 Jun; 11(6):1065-72. PubMed ID: 8671970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 12. Mineral and bone metabolism in thyroid disease: a review.
    Auwerx J; Bouillon R
    Q J Med; 1986 Aug; 60(232):737-52. PubMed ID: 3774957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy?
    Ionova D; Zlatarska S; Kirjakov Z
    Nephrol Dial Transplant; 1995; 10(9):1782. PubMed ID: 8559512
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of biochemical with radiological findings in renal osteodystrophy.
    Moorhead JF; Varghese Z; Tatler GL; Baillod RA; Wills MR
    Ann Clin Biochem; 1975 May; 12(3):126-31. PubMed ID: 15637920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
    Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
    Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical, biochemical and roentgenologic changes in hyperparathyroidism from the viewpoint of the orthopedist].
    Trzenschik K; Mühlbach R
    Z Arztl Fortbild (Jena); 1970 Nov; 64(21):1097-103. PubMed ID: 5505099
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum osteocalcin in metabolic bone diseases: what is its real significance?
    Minisola S; Carnevale V; Pacitti MT; Romagnoli E; Scarnecchia L; Rosso R; Minisola G; Mazzuoli GF
    J Endocrinol Invest; 1993 Apr; 16(4):277-9. PubMed ID: 8514983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between vitamin A and bone disease in chronic renal failure.
    Rylance PB; Brown IR; Howells DW; Nisbet JA; Stone AN; Eastwood JB
    Nephron; 1984; 36(2):131-5. PubMed ID: 6537995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperparathyroidism in chronic renal failure and dialysis osteodystrophy.
    O'Riordan JL; Page J; Kerr DN; Walls J; Moorhead J; Crockett RE; Franz H; Ritz E
    Q J Med; 1970 Jul; 39(155):359-76. PubMed ID: 5478506
    [No Abstract]   [Full Text] [Related]  

  • 20. Alkaline phosphatase isoenzymes in dialysis bone disease.
    Mountokalakis T; Virvidakis C; Nicolaou A; Manousos O
    Br Med J; 1977 Jun; 1(6077):1663. PubMed ID: 871719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.